Targeting BRAF Mutation Positive Cancers: Melanoma, Lung and Colorectal | Roswell Park Comprehensive Cancer Center - Buffalo, NY
Dabrafenib plus Trametinib: Two Kinase Inhibitors Used in Combination to Target Different Parts of the MAPK Pathway | Personalized Medicine in Oncology
BRAF/MEK Inhibitor Combinations Impressive in Melanoma Trials - The ASCO Post
Cancers | Free Full-Text | Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management - Livingstone - Chinese Clinical Oncology
Mechanisms of acquired resistance to BRAF-MEK inhibitors. Multiple... | Download Scientific Diagram
Systemic treatment for BRAF-mutant melanoma: where do we go next? - The Lancet Oncology
Combined BRAF and MEK Inhibition for Patients with Advanced Melanoma
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review - ScienceDirect
Mechanisms of intrinsic resistance to BRAF-MEK inhibitors. Coexistent... | Download Scientific Diagram
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma - Lim - 2017 - Cancer - Wiley Online Library
A combined therapy improves survival in patients with metastatic melanoma | Hospital Clínic Barcelona
IJMS | Free Full-Text | Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation
Cancers | Free Full-Text | Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
The MAPK pathway and the role of BRAF and MEK inhibitors. | Download Scientific Diagram
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models | Journal of Experimental & Clinical Cancer Research | Full Text
Targeted Drug Trio for Colorectal Cancer with BRAF Mutations - NCI
Recent advances in the treatment of melanoma with BRAF and MEK inhibitors - Muñoz-Couselo - Annals of Translational Medicine
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma | Oncogene
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial - The Lancet Oncology
Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma | Nature Reviews Clinical Oncology
Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma - ScienceDirect
MEK inhibitors for the treatment of non-small cell lung cancer | Journal of Hematology & Oncology | Full Text
Dabrafenib plus Trametinib: Two Kinase Inhibitors Used in Combination to Target Different Parts of the MAPK Pathway | Personalized Medicine in Oncology
Figure 1 from Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. | Semantic Scholar
